molecular biology, pharmacology, toxicology, and translational sciences are all necessary to advance biomedical research and is the foundation upon which all of the case studies stand. These previous words of Malcolm MacCoss still ring true to me – “… the noble endeavor of drug discovery must continue to move forward, even if the path is steep and the costs continue to rise. We must persevere because otherwise our children and their children will be restricted to using only the drugs of their parents to fight their battles with the same devastating diseases, despite all the wonderful discoveries in medicine and the biological sciences …” I hope that the readers of this volume are inspired by the case studies described and conclude as I did that despite the great challenges in front of us in combatting human disease, the future provides us with the great opportunity to impact the course of human health.
References
1 1 World Health Organization (2018). The top ten causes of death. https://www.who.int/news‐room/fact‐sheets/detail/the‐top‐10‐causes‐of‐death (accessed 29 September 2021).
2 2 Bloom, D.E. and Cadarette, D. (2019). Infectious disease threats in the twenty‐first century: strengthening the global response. Front. Immunol. 10: 1–12.
3 3 Trypsteen, W., Van Cleemput, J., van Snippenberg, J. et al. (2020). On the whereabouts of SARS‐CoV‐2 in the human body: a systematic review. PLoS Pathog.: 1–26.
4 4 U.S. Department of Health and Human Services(2017). United States life tables, 2017. https://www.cdc.gov/nchs/data/nvsr/nvsr68/nvsr68_07‐508.pdf (accessed 29 September 2021).
5 5 Vogenberg, F.R. (2019). U.S. Healthcare trends and contradictions in 2019. Am. Health Drug Benefits 12 (1): 40–47.
6 6 Hay, M., Thomas, D.W., Craighead, J.L. et al. (2014). Clinical development success rates for investigational drugs. Nat. Biotechnol. 32 (1): 40–51.
7 7 Smietana, K., Siatkowski, M., and Mølle, M. (2016). Trends in clinical success rates. Nat. Rev. Drug Discov. 15: 379–380.
8 8 Thomas, D.W., Burns, J., Audette, J. et al. (2017). Clinical development success rates 2006–2015. https://www.bio.org/sites/default/files/legacy/bioorg/docs/Clinical%20Development%20Success%20Rates%202006‐2015%20‐%20BIO,%20Biomedtracker,%20Amplion%202016.pdf (accessed 29 September 2021).
9 9 Wong, C.H., Siah, W.W., and Lo, A.W. (2019). Estimation of clinical trial success rates and related parameters. Biostatistics 20 (2): 273–286.
10 10 Bansal, R., De Backer, R., and Ranade, V. (2018). What's behind the pharmaceutical sector's M&A push. https://www.mckinsey.com/business‐functions/strategy‐and‐corporate‐finance/our‐insights/whats‐behind‐the‐pharmaceutical‐sectors‐m‐and‐a‐push# (accessed 29 September 2021).
11 11 Patterson, J.A. and Carroll, N.V. (2019). Should the United States regulate prescription drug prices? A critical review. Res. Social Adm. Pharm https://doi.org/10.1016/j.sapharm.2019.06.010.
12 12 Life Sci VC (2019). Venturing a perspective on the drug pricing debate. https://lifescivc.com/2019/12/venturing‐a‐perspective‐on‐the‐drug‐pricing‐debate (accessed 29 September 2021).
13 13 Stoner, I. (2019). Biopharma has abandoned antibiotic development. Here's why we did, too. https://endpts.com/biopharma‐has‐abandoned‐antibiotic‐development‐heres‐why‐we‐did‐too (accessed 29 September 2021).
14 14 McCarthy, J. (2019). Big pharma sinks to the bottom of U.S. industry rankings. https://news.gallup.com/poll/266060/big‐pharma‐sinks‐bottom‐industry‐rankings.aspx (accessed 29 September 2021).
15 15 Lederman, L. (2019). The ever more pressing problem of science literacy. In: Learning to Live Together: Promoting Social Harmony (ed. J. Kelso), 139–147. Cham: Springer.
16 16 Alltucker, K. (2019). Struggling to stay alive: rising insulin prices cause diabetics to go to extremes https://www.usatoday.com/in‐depth/news/50‐states/2019/03/21/diabetes‐insulin‐costs‐diabetics‐drug‐prices‐increase/3196757002 (accessed 29 September 2021).
17 17 Smythe, C. and Geiger, K.(2015). Shkreli, drug price gouger, denies fraud and posts bail. https://www.bloomberg.com/features/2015‐martin‐shkreli‐securities‐fraud (accessed 29 September 2021).
18 18 Ramsey, L. (2018). The rise and fall of Theranos, the blood‐testing startup that went from Silicon Valley darling to facing fraud charges. https://www.businessinsider.com/the‐history‐of‐silicon‐valley‐unicorn‐theranos‐and‐ceo‐elizabeth‐holmes‐2018‐5 (accessed 29 September 2021).
19 19 Ekins, S., Mottin, M., Ramos, P. et al. (2020). Déjà vu: stimulating open drug discovery for SARS‐CoV‐2. Drug Discov. Today 25 (5): 928–941.
20 20 Dubois, M., Ardin, C., André, F. et al. (2019). The revolution of immuno‐oncology therapy: review of immune checkpoint inhibitors efficacy. Med. Sci. (Paris) 35 (12): 937–945.
21 21 Yu, J.X., Hubbard‐Lucey, V.M., and Tang, J. (2019). Immuno‐oncology drug development goes global. Nat. Rev. Drug Discov. 18: 899–900.
22 22 Owen, C., Berinstein, N.L., Christofides, A., and Sehn, L.H. (2019). Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma. Curr. Oncol. 26 (2): e233–e240.
23 23 Zinman, B., Wanner, C., Lachin, J.M. et al. (2015). Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373 (22): 2117–2128.
24 24 Pontali, E., Raviglione, M.C., Migliori, G.B., and the writing group members of the Global TB Network Clinical Trials Committee (2019). Regimens to treat multidrug‐resistant tuberculosis: past, present and future perspectives. Eur. Respir. Rev. 28: 1–7.
25 25 Morgan, P., Brown, D.G., Lennard, S. et al. (2018). Impact of a five‐dimensional framework on R&D productivity at AstraZeneca. Nat. Rev. Drug Discov. 17: 167–181.
26 26 Disney, M.D., Dwyer, B.G., and Childs‐Disney, J.L. (2018). Drugging the RNA world. Cold Spring Harb. Perspect. Biol. 10: 1–15.
27 27 Dang, C.V., Reddy, E.P., Shokat, K.M., and Soucek, L. (2017). Drugging the ‘Undruggable’ cancer targets. Nat. Rev. Cancer 17: 502–508.
28 28
